| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 21027 |
| Drug | Vericiguat |
| Brand | Verquvo® |
| Indication | For the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilised after a recent decompensation event requiring intravenous therapy. |
| Assessment Process | |
| Rapid review commissioned | 21/06/2021 |
| Rapid review completed | 15/07/2021 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of vericiguat compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 24/08/2021 |
| Pre-submission consultation with Applicant | 20/09/2021 |
| Full submission received from Applicant | 21/03/2022 |
| Preliminary review sent to Applicant | 09/06/2022 |
| NCPE assessment re-commenced | 04/07/2022 |
| Factual accuracy sent to Applicant | 12/07/2022 |
| NCPE assessment re-commenced | 20/07/2022 |
| NCPE assessment completed | 28/07/2022 |
| NCPE assessment outcome | The NCPE recommends that vericiguat not be considered for reimbursement* |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013
